Abstract
Low-dose, subcutaneous recombinant human granulocyte colony-stimulating factor (rHuG-CSF, Lenograstim®) was administered to 40 cancer patients (17 men, 23 women) enrolled from two medical centers to verify its clinical effectiveness and safety. The patient's mean age was 50.3 ± 14.9 years. In this study, there were 20 patients with non-Hodgkin's lymphoma, 10 with breast cancer and 10 with various other solid tumors. The patients first received a course of chemotherapy without rHuG-CSF (control cycle). All patients had at least one episode of neutropenia or leukopenia during the control cycle. rHuG-CSF (2 μg/kg/day) was given subcutaneously for 10 days during the study cycle starting on the fourth day of chemotherapy. The nadirs of absolute neutrophil counts (ANC) were 1.8 ± 0.25 x 109/L and 0.27 ± 0.05 x 109/L for the rHuG-CSF cycle and pre-rHuG-CSF control cycle, respectively. The number of days of ANC <1 x 109/L were 1.03 ± 0.29 and 7.38 ± 0.58 for rHuG-CSF and control cycles, respectively. The duration from nadir to recovery of ANC (≤ 2 x 109/L) was 9.68 ± 1.15 days in the rHuG-CSF cycle, vs 22.53 ± 1.03 days in control cycle (p <0.0001). No patient withdrew from the study. Adverse events were mild, with 12.5% to 40% of patients developing myalgia, general malaise, back pain, anorexia or fever. These side-effects were tolerable in all cases. The biochemical abnormalities were subtle and negligible. rHuG-CSF 2μg/kg/day given subcutaneously for 10 days beginning on the fourth day of chemotherapy is very effective (90%), safe and convenient.
| Original language | English |
|---|---|
| Pages (from-to) | 845-850 |
| Number of pages | 6 |
| Journal | Journal of the Formosan Medical Association = Taiwan yi zhi |
| Volume | 95 |
| Issue number | 11 |
| Publication status | Published - Nov 1996 |
| Externally published | Yes |
Fingerprint
Keywords
- (rHuG-CSF)
- cancer chemotherapy
- neutropenia
- recombinant human granulocyte colony-stimulating factor
ASJC Scopus subject areas
- Medicine(all)
Cite this
Clinical trial of low-dose rHuG-CSF in neutropenic cancer patients following anti-cancer chemotherapy. / Chang, Ming Chih; Lai, Gi Ming; Tsan, Kun Wu; Wang, Ruen Sheng; Wu, Ji Hong.
In: Journal of the Formosan Medical Association = Taiwan yi zhi, Vol. 95, No. 11, 11.1996, p. 845-850.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical trial of low-dose rHuG-CSF in neutropenic cancer patients following anti-cancer chemotherapy
AU - Chang, Ming Chih
AU - Lai, Gi Ming
AU - Tsan, Kun Wu
AU - Wang, Ruen Sheng
AU - Wu, Ji Hong
PY - 1996/11
Y1 - 1996/11
N2 - Low-dose, subcutaneous recombinant human granulocyte colony-stimulating factor (rHuG-CSF, Lenograstim®) was administered to 40 cancer patients (17 men, 23 women) enrolled from two medical centers to verify its clinical effectiveness and safety. The patient's mean age was 50.3 ± 14.9 years. In this study, there were 20 patients with non-Hodgkin's lymphoma, 10 with breast cancer and 10 with various other solid tumors. The patients first received a course of chemotherapy without rHuG-CSF (control cycle). All patients had at least one episode of neutropenia or leukopenia during the control cycle. rHuG-CSF (2 μg/kg/day) was given subcutaneously for 10 days during the study cycle starting on the fourth day of chemotherapy. The nadirs of absolute neutrophil counts (ANC) were 1.8 ± 0.25 x 109/L and 0.27 ± 0.05 x 109/L for the rHuG-CSF cycle and pre-rHuG-CSF control cycle, respectively. The number of days of ANC <1 x 109/L were 1.03 ± 0.29 and 7.38 ± 0.58 for rHuG-CSF and control cycles, respectively. The duration from nadir to recovery of ANC (≤ 2 x 109/L) was 9.68 ± 1.15 days in the rHuG-CSF cycle, vs 22.53 ± 1.03 days in control cycle (p <0.0001). No patient withdrew from the study. Adverse events were mild, with 12.5% to 40% of patients developing myalgia, general malaise, back pain, anorexia or fever. These side-effects were tolerable in all cases. The biochemical abnormalities were subtle and negligible. rHuG-CSF 2μg/kg/day given subcutaneously for 10 days beginning on the fourth day of chemotherapy is very effective (90%), safe and convenient.
AB - Low-dose, subcutaneous recombinant human granulocyte colony-stimulating factor (rHuG-CSF, Lenograstim®) was administered to 40 cancer patients (17 men, 23 women) enrolled from two medical centers to verify its clinical effectiveness and safety. The patient's mean age was 50.3 ± 14.9 years. In this study, there were 20 patients with non-Hodgkin's lymphoma, 10 with breast cancer and 10 with various other solid tumors. The patients first received a course of chemotherapy without rHuG-CSF (control cycle). All patients had at least one episode of neutropenia or leukopenia during the control cycle. rHuG-CSF (2 μg/kg/day) was given subcutaneously for 10 days during the study cycle starting on the fourth day of chemotherapy. The nadirs of absolute neutrophil counts (ANC) were 1.8 ± 0.25 x 109/L and 0.27 ± 0.05 x 109/L for the rHuG-CSF cycle and pre-rHuG-CSF control cycle, respectively. The number of days of ANC <1 x 109/L were 1.03 ± 0.29 and 7.38 ± 0.58 for rHuG-CSF and control cycles, respectively. The duration from nadir to recovery of ANC (≤ 2 x 109/L) was 9.68 ± 1.15 days in the rHuG-CSF cycle, vs 22.53 ± 1.03 days in control cycle (p <0.0001). No patient withdrew from the study. Adverse events were mild, with 12.5% to 40% of patients developing myalgia, general malaise, back pain, anorexia or fever. These side-effects were tolerable in all cases. The biochemical abnormalities were subtle and negligible. rHuG-CSF 2μg/kg/day given subcutaneously for 10 days beginning on the fourth day of chemotherapy is very effective (90%), safe and convenient.
KW - (rHuG-CSF)
KW - cancer chemotherapy
KW - neutropenia
KW - recombinant human granulocyte colony-stimulating factor
UR - http://www.scopus.com/inward/record.url?scp=0030450452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030450452&partnerID=8YFLogxK
M3 - Article
C2 - 8990772
AN - SCOPUS:0030450452
VL - 95
SP - 845
EP - 850
JO - Journal of the Formosan Medical Association
JF - Journal of the Formosan Medical Association
SN - 0929-6646
IS - 11
ER -